HRTS.US Tema Cardiovascular and Metabolic ETF
- Total assets
- 58.4M
- Expense ratio
- 0.76%
- Dividend yield
- 1.24%
- 1-year return
- +17.20%
- Holdings
- 45
- Since
- 2023
Fund data as reported by the issuer, updated Nov 15, 2026. Total assets are in the fund's base currency.
What does HRTS.US invest in?
- Mostly US stocks (81.1%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (79.3%)
- Top 3 holdings: 22.3% of the fund
Asset allocation
- US stocks 81.1%
- Non-US stocks 18.8%
Top holdings
- Eli Lilly and Company 13.02%
- Thermo Fisher Scientific Inc 5.05%
- Kodiak Sciences Inc 4.22%
- Merck & Company Inc 4.22%
- Roche Holding Ltd ADR 4.13%
Tema Cardiovascular and Metabolic ETF performance
Sharpe ratio 0.00- This year
- +11.27%
- 1 year
- +17.20%
- 3 years
- -
- 5 years
- -
Volatility 15.9% over 1 year. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
HRTS.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Tema Cardiovascular and Metabolic ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 co…
Full fund profileTema Cardiovascular and Metabolic ETF top holdings
47.3% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Eli Lilly and Company LLY.US | Healthcare | United States | 13.02% |
| Thermo Fisher Scientific Inc TMO.US | Healthcare | United States | 5.05% |
| Kodiak Sciences Inc KOD.US | Healthcare | United States | 4.22% |
| Merck & Company Inc MRK.US | Healthcare | United States | 4.22% |
| Roche Holding Ltd ADR RHHBY.US | Healthcare | United States | 4.13% |
| BridgeBio Pharma Inc BBIO.US | Healthcare | United States | 3.60% |
| Gilead Sciences Inc GILD.US | Healthcare | United States | 3.39% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 3.29% |
| UnitedHealth Group Incorporated UNH.US | Healthcare | United States | 3.21% |
| Danaher Corporation DHR.US | Healthcare | United States | 3.14% |
The 10 largest of 45 holdings.
HRTS.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
HRTS.US regional exposure
- North America79.3%
- Europe Developed11.6%
- United Kingdom3.0%
- Japan2.5%
- Africa/Middle East1.3%
Share of the stocks in the fund.
Company size
Average market cap 127B- Mega cap27.9%
- Big cap45.4%
- Medium cap11.4%
- Small cap13.7%
- Micro cap1.7%
Tema Cardiovascular and Metabolic ETF fund profile
- Fund name
- Tema Cardiovascular and Metabolic ETF
- Ticker
- HRTS.US
- Exchange
- USA Stocks
- Issuer
- Tema ETFs
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Nov 20, 2023
- Trading currency
- USD
- Expense ratio
- 0.76%
About Tema Cardiovascular and Metabolic ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.